DELRAY BEACH, Fla., April 25, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Company's case remains scheduled on the Court's five (5) week trial docket commencing May 2, 2005.
At the calendar call on April, 22nd, Defendants attorney renewed the Motion For Continuance of the trial date, which the Court denied.
According to the Court's trial schedule, announced at the calendar call, HTTD's trial should commence during the latter part of May. The Court will be presiding over a trial commencing on May 9th that could last for two weeks. Other, shorter trials, are then scheduled. You can monitor the trial date by signing onto the website: www.flsd.uscourts.gov and clicking on "Honorable Daniel T. K. Hurley". As the Court's website states, "Suggested start-up dates are advisory only. Due to settlements and other reasons, the Court reserves the right to call cases for trial earlier than the listed date and out of turn."
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's shareholders and investors will be kept informed of all public developments as they occur regarding the above matters. In order to ensure the confidentiality of the Company's business and legal strategies, certain specific information may not be immediately available. Once such information can be revealed, it will be publicly disclosed to all shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com.
Cautionary Note Regarding Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this news release may contain or constitute forward-looking statements. These forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions of the Private Securities Litigation Act of 1995, Hard to Treat Diseases, Inc. provides the following cautionary statement identifying important factors which, among others, could cause the actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.